{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:09:24Z","timestamp":1792091364671,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Scientific Fund of the Mayor of the City of Vienna","award":["14016"],"award-info":[{"award-number":["14016"]}]},{"name":"Anniversary Fund of the Austrian National Bank","award":["16155"],"award-info":[{"award-number":["16155"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In patients with acute coronary syndrome (ACS), angiotensin-converting enzyme (ACE) inhibitors are preferred over angiotensin receptor blockers (ARBs). However, in a recent pilot study, treatment with ACE inhibitors was associated with increased platelet reactivity compared to ARBs. Therefore, we sought to investigate the impact of renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitors and ARBs on platelet aggregation in patients with ACS undergoing percutaneous coronary intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>On-treatment residual platelet reactivity in response to arachidonic acid (AA), adenosine diphosphate (ADP), SFLLRN, AYPGKF, and collagen was assessed by multiple electrode aggregometry (MEA) in 197 ACS patients on dual antiplatelet therapy (DAPT) with aspirin and either prasugrel or ticagrelor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred sixty-five (83.7%) patients were treated with ACE inhibitors, 32 (16.3%) with ARBs. On-treatment residual AA- and ADP-inducible platelet reactivity was significantly higher in patients with ACE inhibitors (both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Likewise, SFLLRN was significantly higher in patients with ACE inhibitors (<jats:italic>p<\/jats:italic>\u2009=\u20090.036) and there was a trend for higher AYPGKF- and collagen-inducible platelet reactivity (<jats:italic>p<\/jats:italic>\u2009=\u20090.053 and <jats:italic>p<\/jats:italic>\u2009=\u20090.082). The incidence of high on-treatment residual platelet reactivity AA was significantly higher in patients with ACE inhibitors (52 [31.5%] vs. 3 [9.4%] patients; <jats:italic>p<\/jats:italic>\u2009=\u20090.019).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ACE inhibitors are associated with increased on-treatment residual platelet reactivity in ACS patients with potent DAPT. Further clinical trials are needed to elucidate the role of RAAS blockade with ACE inhibitors and ARBs in ACS patients treated according to current standards.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-020-07128-0","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T08:02:44Z","timestamp":1608278564000},"page":"1183-1190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-628X","authenticated-orcid":false,"given":"Maximilian","family":"Tscharre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia P.","family":"Wadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Weikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pultar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Eichelberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Panzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gremmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"issue":"3","key":"7128_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/1074248419899314","volume":"25","author":"M Tscharre","year":"2020","unstructured":"Tscharre M, Michelson AD, Gremmel T. Novel antiplatelet agents in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2020;25(3):191\u2013200. https:\/\/doi.org\/10.1177\/1074248419899314.","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"7128_CR2","doi-asserted-by":"publisher","unstructured":"Collet J-P, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;1\u201379. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575.","DOI":"10.1093\/eurheartj\/ehaa575"},{"key":"7128_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119\u201377.","journal-title":"Eur Heart J"},{"key":"7128_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"7128_CR5","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"7128_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/rth2.12115","volume":"2","author":"T Gremmel","year":"2018","unstructured":"Gremmel T, Michelson AD, Frelinger AL, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost. 2018;2:439\u201349.","journal-title":"Res Pract Thromb Haemost"},{"key":"7128_CR7","doi-asserted-by":"publisher","first-page":"e13102","DOI":"10.1111\/eci.13102","volume":"49","author":"M Winter","year":"2019","unstructured":"Winter M, Schneeweiss T, Cremer R, Biesinger B, Hengstenberg C, Pr\u00fcller F, et al. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Investig. 2019;49:e13102.","journal-title":"Eur J Clin Investig"},{"key":"7128_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1160\/TH09-03-0192","volume":"102","author":"L Jennings","year":"2009","unstructured":"Jennings L. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009;102:248\u201357.","journal-title":"Thromb Haemost"},{"key":"7128_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/rth2.12213","volume":"3","author":"PP Wadowski","year":"2019","unstructured":"Wadowski PP, Pultar J, Weikert C, Eichelberger B, Panzer B, Huber K, et al. Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y 12 inhibitors. Res Pract Thromb Haemost. 2019;3:383\u201390.","journal-title":"Res Pract Thromb Haemost"},{"key":"7128_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijcard.2012.09.103","volume":"168","author":"R Badr Eslam","year":"2013","unstructured":"Badr Eslam R, Lang IM, Koppensteiner R, Calatzis A, Panzer S, Gremmel T. Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. Int J Cardiol. 2013;168:403\u20136.","journal-title":"Int J Cardiol"},{"key":"7128_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/1755-5922.12138","volume":"33","author":"T Gremmel","year":"2015","unstructured":"Gremmel T, Durstberger M, Eichelberger B, Koppensteiner R, Panzer S. Calcium-channel blockers attenuate the antiplatelet effect of clopidogrel. Cardiovasc Ther. 2015;33:264\u20139.","journal-title":"Cardiovasc Ther"},{"key":"7128_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/hrt.2009.171488","volume":"96","author":"T Gremmel","year":"2010","unstructured":"Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart. 2010;96:186\u20139.","journal-title":"Heart."},{"key":"7128_CR13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/eurheartj\/ehq023","volume":"31","author":"D Sibbing","year":"2010","unstructured":"Sibbing D, von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J. 2010;31:1205\u201311.","journal-title":"Eur Heart J"},{"key":"7128_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","volume":"51","author":"M Gilard","year":"2008","unstructured":"Gilard M, Arnaud B, Cornily J-C, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol. 2008;51:256\u201360.","journal-title":"J Am Coll Cardiol"},{"key":"7128_CR15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s00228-020-02915-y","volume":"76","author":"C Helten","year":"2020","unstructured":"Helten C, Mourikis P, Dannenberg L, M\u2019Pembele R, Trojovsky K, Ayhan A, et al. A novel mechanism of ACE inhibition\u2013associated enhanced platelet reactivity: disproof of the ARB-MI paradox? Eur J Clin Pharmacol. 2020;76:1245\u201351.","journal-title":"Eur J Clin Pharmacol"},{"key":"7128_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.2165\/00003495-199040040-00003","volume":"40","author":"M Verstraete","year":"1990","unstructured":"Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs. 1990;40:498\u2013530.","journal-title":"Drugs."},{"key":"7128_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jacc.2014.05.049","volume":"64","author":"K Mayer","year":"2014","unstructured":"Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, et al. Aspirin treatment and outcomes after percutaneous coronary intervention. J Am Coll Cardiol. 2014;64:863\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"7128_CR18","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","volume":"12","author":"D Sibbing","year":"2019","unstructured":"Sibbing D, Aradi D, Alexopoulos D, ten Berg J, Bhatt DL, Bonello L, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12:1521\u201337.","journal-title":"JACC Cardiovasc Interv"},{"key":"7128_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nrd2957","volume":"9","author":"AD Michelson","year":"2010","unstructured":"Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010;9:154\u201369.","journal-title":"Nat Rev Drug Discov"},{"key":"7128_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0035-1564835","volume":"42","author":"T Gremmel","year":"2016","unstructured":"Gremmel T, Frelinger A, Michelson A. Platelet physiology. Semin Thromb Hemost. 2016;42:191\u2013204.","journal-title":"Semin Thromb Hemost"},{"key":"7128_CR21","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension. J Am Coll Cardiol. 2018;71:1474\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"7128_CR22","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","volume":"97","author":"ACE Inhibitor Myocardial Infarction Collaborative Group","year":"1998","unstructured":"ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Circulation. 1998;97:2202\u201312.","journal-title":"Circulation."},{"key":"7128_CR23","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360:752\u201360.","journal-title":"Lancet."},{"key":"7128_CR24","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, K\u00f8ber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893\u2013906.","journal-title":"N Engl J Med"},{"key":"7128_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","volume":"91","author":"S Bangalore","year":"2016","unstructured":"Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc. 2016;91:51\u201360.","journal-title":"Mayo Clin Proc"},{"key":"7128_CR26","doi-asserted-by":"publisher","first-page":"g6650","DOI":"10.1136\/bmj.g6650","volume":"349","author":"JH Yang","year":"2014","unstructured":"Yang JH, Hahn J-Y, Bin SY, Choi S-H, Choi J-H, Lee SH, et al. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study. BMJ. 2014;349:g6650.","journal-title":"BMJ"},{"key":"7128_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/eci.12094","volume":"43","author":"T Gremmel","year":"2013","unstructured":"Gremmel T, Kopp CW, Seidinger D, Koppensteiner R, Steiner S, Panzer S. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. Eur J Clin Investig. 2013;43:689\u201397.","journal-title":"Eur J Clin Investig"},{"key":"7128_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1160\/TH13-07-0558","volume":"111","author":"T Gremmel","year":"2014","unstructured":"Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp C. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost. 2014;111:474\u201382.","journal-title":"Thromb Haemost"},{"key":"7128_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van De Werf F, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20\u201333.","journal-title":"N Engl J Med"},{"key":"7128_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jacc.2004.03.065","volume":"44","author":"B Schieffer","year":"2004","unstructured":"Schieffer B, B\u00fcnte C, Witte J, Hoeper K, B\u00f6ger RH, Schwedhelm E, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44:362\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"7128_CR31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","volume":"53","author":"D Sibbing","year":"2009","unstructured":"Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Sch\u00f6mig A, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:849\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"7128_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1160\/TH11-03-0137","volume":"106","author":"T Gremmel","year":"2011","unstructured":"Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response\/non response to clopidogrel. Thromb Haemost. 2011;106:211\u20138.","journal-title":"Thromb Haemost"},{"key":"7128_CR33","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jacc.2003.12.034","volume":"43","author":"W-H Chen","year":"2004","unstructured":"Chen W-H, Lee P-Y, Ng W, Tse H-F, Lau C-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004;43:1122\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"7128_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/AC.67.4.2170686","volume":"67","author":"SI Al-Azzam","year":"2012","unstructured":"Al-Azzam SI, Alzoubi KH, Khabour O, Alowidi A, Tawalbeh D. The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. Acta Cardiol. 2012;67:445\u20138.","journal-title":"Acta Cardiol"},{"key":"7128_CR35","doi-asserted-by":"publisher","unstructured":"Von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A. Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays: PFA-100 and multiple electrode aggregometry. 2007;27(3):155\u201360. https:\/\/doi.org\/10.1007\/978-3-540-36715-4_49.","DOI":"10.1007\/978-3-540-36715-4_49"},{"key":"7128_CR36","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1080\/09537104.2016.1190007","volume":"27","author":"I Bernlochner","year":"2016","unstructured":"Bernlochner I, Mayer K, Orban M, Morath T, Jaitner J, R\u00f6ssner L, et al. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: the ISAR-ADAPT-PF study. Platelets. 2016;27:796\u2013804.","journal-title":"Platelets."},{"key":"7128_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10557-019-06932-7","volume":"34","author":"PP Wadowski","year":"2020","unstructured":"Wadowski PP, Weikert C, Pultar J, Lee S, Eichelberger B, Koppensteiner R, et al. Ticagrelor inhibits toll-like and protease-activated receptor mediated platelet activation in acute coronary syndromes. Cardiovasc Drugs Ther. 2020;34:53\u201363.","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07128-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07128-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07128-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T10:29:55Z","timestamp":1636453795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07128-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7128"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07128-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"assertion":[{"value":"10 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by the local Ethics Committee of the Medical University of Vienna and was in accordance with the Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Written informed consent was obtained from all study participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All statistical analyses were generated with Statistical Package for Social Sciences (IBM SPSS version 24, Armonk, New York, USA) and R 3.6.3.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}